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Abstract: Gemcitabine is a pyrimidine nucleoside antimetabolite agent which is active in several 
human malignancies, including nonsmall cell lung cancer (NSCLC). Because of its acceptable 
toxicity profile, with myelosuppression being the most common adverse event, gemcitabine 
can be safely combined with a number of cytotoxic agents, including platinum derivatives and 
new-generation anticancer compounds. In fact, the combination of gemcitabine and cisplatin is a 
first-line treatment for patients with advanced NSCLC, pharmacoeconomic data indicating that 
it represents the most cost-effective regimen among platinum-based combinations with third-
generation cytotoxic drugs. The drug has been investigated in the context of nonplatinum-based 
regimens in a number of prospective clinical trials, and might provide a suitable alternative for 
patients with contraindications to platinum. Recently, gemcitabine-based doublets have been 
successfully tested in association with novel targeted agents with encouraging results, providing 
further evidence for the role of the drug in the treatment of NSCLC. In the last few years several 
attempts have been pursued in order to identify molecular predictors of gemcitabine activity, 
and recent data support the feasibility of genomic-based approaches to customize treatment 
with the ultimate goal of improving patient outcome.
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Introduction
Lung cancer is the leading cause of cancer-related death in both men and women 
worldwide, thus representing a major healthcare issue.1 Nonsmall cell lung cancer 
(NSCLC) accounts for the vast majority of the cases, adenocarcinoma and squamous 
cell carcinoma being the most frequent histotypes. Although recent advances in the 
knowledge of lung cancer biology led to the development of new effective targeted 
agents directed against pathways that are selectively activated in cancer, platinum-
based chemotherapy remains the mainstay of treatment for unselected patients with 
advanced disease.2 Among third-generation cytotoxic compounds, gemcitabine, 
a pyrimidine nucleoside antimetabolite, has been demonstrated to be one of the most 
effective agents, particularly when administered in combination regimens.
Compound characteristics
Mechanism of action
Gemcitabine (2´deoxy-2´2´-difluorocytidine monohydrochloride), is a potent and 
specific pyrimidine nucleoside antimetabolite which is structurally analogous to deoxy-
cytidine. Due to its hydrophilic nature, the drug requires to be actively introduced into the 
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transporter-1 (hENT1) and, to a lesser extent, the human 
concentrative nucleoside transporter-1 and -3 (hCNT-1, 
hCNT-3).3 On uptake into the cells, gemcitabine can be either 
deaminated to an inactive form, 2´, 2´-difluorodeoxyuridine 
(dFdU) by cytidine deaminase (CDA), or phosphorylated 
by deoxycytidine kinase (dCK) to dFdC-5´-monophosphate 
(dFdCMP) and to the active metabolites diphosphate and 
triphosphate.4 While dFdC-5´-diphosphate can inhibit 
ribonucleotide reductase (RR), an enzyme essential for 
the production of deoxyribonucleotides prior to DNA 
synthesis in S phase of dividing cells, dFdC-5´-triphosphate 
is incorporated into DNA resulting in early termination of 
DNA synthesis.4
Toxicity
Gemcitabine has an extremely favorable toxicity profile, a 
feature that has prompted the investigation of the agent in 
combination with other cytotoxic compounds. Myelosuppres-
sion represents the main dose-limiting toxicity and occurs 
in approximately two-thirds of the patients that receive the 
drug as single agent over a standard 30-minute infusion, 
about 25% of individuals experiencing grade 3 and 4 neutro-
penia.5 Nevertheless, 1% of the patients require treatment 
discontinuation for hematologic toxicity, while red blood cell 
transfusions can be necessary in up to 20% of the patients, 
according to pancreatic cancer studies.5 Other commonly 
observed adverse events include gastrointestinal toxicity, 
mild to moderate nausea and vomiting being reported in 
about 70% of patients, and transient elevation of serum trans-
aminases in 70%, but with no evidence of increasing hepatic 
toxicity with either longer duration of exposure to the drug or 
with greater total cumulative dose.5 In addition, gemcitabine 
might cause mild proteinuria (45%) and hematuria (35%), 
fever (40%), and rash (30%).5
Dosage
Gemcitabine is commonly administered weekly at 1000 or 
1250 mg/m2 as a 30-minute intravenous infusion for 2 or 
3 weeks followed by a week of rest. This schedule seems to 
provide the best compromise in terms of toxicity and dose 
intensity in NSCLC patients.6 In fact, deoxycitidine kinase is 
saturated at plasma concentrations achieved after a 30-minute 
infusion.7,8 However, the optimal plasma drug concentration 
that maximizes the rate of formation of gemcitabine triphos-
phate is 20 µmol/Lµ, a target value that can be achieved 
with dose rates of about 10 mg/m2/min (prolonged infusion), 
according to phase I trials.7,8 For this reason, accumulation of 
higher intracellular gemcitabine triphosphate concentration, 
which may result in enhanced cytotoxic activity, can be 
reached by prolonged infusion rates rather than increased 
drug dose. This hypothesis has been tested in a number of 
phase II randomized studies with gemcitabine administered 
either as single agent or in combination with cisplatin, 
producing conflicting results.9–11 Because of the lack of 
clear superiority in terms of activity and/or toxicity favoring 
the prolonged infusion rate, a 30-minute infusion schedule 
should remain the standard modality for gemcitabine admin-
istration in patients with advanced NSCLC.
Gemcitabine in platinum-based 
combinations
Platinum-based chemotherapy has been shown for almost 
15 years to significantly improve survival and quality of 
life in patients with advanced NSCLC.12 Since its early 
development gemcitabine has emerged as an ideal partner 
for platinum compounds, because of its theoretical ability of 
interfering with the inhibition of repair of platinum-induced 
DNA damage. Based on the results of several phase III 
trials,13–17 gemcitabine in combination with cisplatin now 
represents a commonly used first-line treatment for patients 
with advanced NSCLC, particularly in Europe.
At least three phase III studies compared a gemcitabine/
cisplatin regimen (GC) with first-generation cisplatin-based 
combinations or cisplatin alone in the first line setting.13–15 The 
Italian Lung Cancer Project investigated the role of the GC 
regimen in comparison with mitomycin/ifosfamide/cisplatin 
(MIC) in 307 advanced NSCLC patients.13 Subjects in the 
GC arm experienced a significantly higher response rate 
(38% vs 26%, P = 0.02) with no difference in survival and 
quality of life as compared with the old-generation regimen. 
The two treatments showed different toxicity profiles. In fact, 
grade 3 and 4 thrombocytopenia was significantly worse in 
the GC arm (64% vs 28%, P  0.001), whereas grade 3 and 
4 alopecia was observed more commonly in the MIC arm 
(39% vs 12%, P  0.001). Further evidence in favour of a 
role for gemcitabine in this setting came from two additional 
phase III trials. In the Spanish study, 135 patients with 
advanced disease were randomly assigned to cisplatin with 
etoposide or gemcitabine.14 Despite the lack of a survival 
benefit, patients treated in the experimental arm reported a 
significantly higher response rate (40.6% vs 21.9%, P = 0.02) 
and time to progression (6.9 vs 4.3 months, P = 0.01), with 
an overall similar toxicity profile. In the study performed by 
the Hoosier Oncology Group, the association of gemcitabine 
and cisplatin has been compared with cisplatin single-agent 
as first line treatment in 522 advanced NSCLC patients.15 OncoTargets and Therapy 2009:2 211
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The GC arm produced a significant improvement over 
single-agent cisplatin with regard to response rate (30.4% vs 
11.1%, P  0.0001), median time to progression (5.6 vs 
3.7 months, P = 0.0013), and overall survival (9.1 vs 7.6 
months, P = 0.004), despite a higher incidence of adverse 
events, mainly hematological.
Due to the development of multiple third-generation 
cytotoxic agents that can be safely and effectively incorpo-
rated in platinum-based regimens, phase III studies have tried 
to identify whether one combination is superior to the others 
in terms of activity and toxicity profile16–18 (Table 1). The 
Eastern Cooperative Oncology Group (ECOG) randomized 
1207 patients to either a reference arm of paclitaxel/cispla-
tin (PC) or one of three experimental arms, including GC, 
docetaxel/cisplatin (DC) or paclitaxel/carboplatin (PCb).16 
None of the four regimens exhibited superior response rate or 
survival, while patients in the GC arm experienced a signifi-
cantly longer time to progression when compared with those 
in the reference arm (4.2 vs 3.4 months, P = 0.001). Similar 
results were reported by the Italian Lung Cancer Project trial, 
where 612 patients with advanced NSCLC were randomly 
allocated to GC, PCb or vinorelbine/cisplatin (VC).17 Again, 
all the regimens showed comparable activity in terms of 
response rate, time to progression and overall survival. More 
recently, the GC regimen has been chosen as a reference arm 
to be compared with an experimental pemetrexed/cisplatin 
(PmC) combination in 1725 chemonaive patients.18 While 
the study met its primary end point of noninferior survival 
for the PmC over the GC arm, GC produced a significantly 
longer overall survival in the subgroup of patients with 
squamous cell histology. This retrospective finding suggests 
that clinically-selected subsets of patients might derive a 
substantial benefit from platinum-based combinations includ-
ing gemcitabine.
Pharmacoeconomic considerations
The similar activity of new generation platinum-based 
regimens observed in phase III trials prompted investigators 
to analyze cost-effectiveness parameters to better identify an 
optimal combination for the first-line treatment of advanced 
NSCLC. Two different pharmacoeconomic evaluations 
performed in the context of the ECOG trial showed that 
the association of cisplatin and gemcitabine was associated 
with the lowest total treatment-related costs when directly 
compared with the two paclitaxel-containing regimens, 
mostly due to the higher costs of chemotherapy in the PC 
arm.19,20 Total costs were similar in the GC and DC arm in 
Germany, France and in the UK, whereas the GC regimen 
was associated with lower total costs in Spain and Italy over 
the docetaxel arm.19 Overall, these data indicate that the GC 
regimen was associated with lower total costs than VC, PC 
and PCb, and similar costs when compared with DC regimen. 
PCb, which is commonly used as a first-line treatment in the 
US, has emerged as the most costly regimen in this study, 
primarily due to the greater acquisition cost of carboplatin 
as compared with cisplatin.
Novello et al conducted a cost-minimization assessment 
aimed at comparing the GC, PCb and VC regimens in 
the study by the Italian Lung Cancer Project.21 Total 
treatment-related costs were lower for the GC regimen over 
PCb and VC combinations. Drug acquisition represented 
a major determinant of total cost particularly for the PCb 
regimen, and thus representing the predominant factor 
responsible for the higher cost of this combination. On the 
other hand, the median cost saving favoring GC over VC 
was predominantly due to the higher hospitalization costs 
in the vinorelbine arm.
Pimentel et al have recently published a pharmacoeco-
nomic evaluation of five platinum-based combinations from 
the perspective of the Portuguese National Health Service, 
pooling data from the ECOG and Italian Lung Cancer 
Project trials.22 Consistent with previous observations, the 
authors confirmed the favorable economic impact of the GC 
combination when compared with the other regimes. Taken 
together, these data suggest the association of gemcitabine 
and cisplatin represents a cost-effective option for the first-
line treatment of advanced NSCLC patients.
Table 1 Phase iii trials comparing new generation platinum-based 
doublets
Trial Regimens N RR  
(%)
OS  
(months)
Pa
eCOG e159416 PC 292 21 7.8 NSb
GC 288 21 8.1
DC 293 17 7.4
PCb 299 15 8.1
iLCP17 vC 203 30 9.5 NSc
GC 205 30 9.8
PCb 204 32 9.9
H3e-MC-JMDB18 GC 863 28.2 10.3 NS
  PmC 862 30.6 10.3  
arelated to overall survival. bPC versus each other regimen. cvC versus each other 
regimen.
Abbreviations: eCOG, east Cooperative Oncology Group; iLCP, italian Lung 
Cancer Project; C, cisplatin; Cb, carboplatin; D, docetaxel; G, gemcitabine; P, paclitaxel; 
Pm, pemetrexed;   v, vinorelbine; rr, response rate; OS, overall survival; NS, not 
significant.OncoTargets and Therapy 2009:2 212
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Gemcitabine in nonplatinum-based 
combinations
Toxicity issues related to the administration of cisplatin led 
investigators to explore the role of combinations of third 
generation cytotoxic agents in nonplatinum-based regimens, 
with gemcitabine being one of the most investigated drugs. 
Several compounds have been associated with gemcitabine, 
including vinorelbine and, above all, taxanes (Table 2). Italian 
investigators performed a phase III trial aimed at comparing 
gemcitabine/vinorelbine (GV) with either VC or GC.23 Patients 
allocated in the cisplatin-based arms had a significantly longer 
progression-free survival (23 vs 17 weeks, P = 0.004) and a 
trend toward improved survival (38 vs 32 weeks, P = 0.08), 
albeit comparable response rate and worse toxicity. Two 
additional studies, however, showed that the association of 
gemcitabine and vinorelbine can compare well with platinum-
based treatments.24,25 In fact, German and Swiss investigators 
reported neither overall nor event-free survival difference 
when comparing a GV combination with an unconventional 
gemcitabine/vinorelbine/cisplatin triplet.24 More recently, a 
Japanese phase III trial compared a GV regimen followed by 
docetaxel with PCb in 401 patients with advanced disease.25 
Despite a significantly higher response rate for patients who 
received PCb (37% vs 25%, P = 0.012), the two arms had 
comparable overall and progression-free survival, indicating 
that this strategy might be a suitable alternative for patients 
with contraindications to platinum.
The association of gemcitabine and docetaxel (GD) has 
been explored by Greek investigators in two phase III trials 
in untreated NSCLC patients.26,27 Particularly, in the first 
published study, the GD arm showed similar activity compared 
with a standard VC regimen, but with a significantly better 
toxicity profile.26 Similar results emerged from a French trial 
conducted in 311 untreated patients,28 thus confirming the 
activity of the regimen and its favorable toxicity profile. More 
data are now available for the association of gemcitabine 
and paclitaxel (GP), which has been extensively character-
ized in at least three phase III studies enrolling more than 
1500 patients.29–31 The new regimen showed comparable 
activity and toxicity with carboplatin-based combinations, 
but a trend towards lower efficacy compared with cisplatin-
containing doublets, raising concerns about its applicability 
in clinical practice. Nevertheless, it should be noted that a 
meta-analysis performed to address the role of nonplatinum 
chemotherapy in the first-line treatment of advanced NSCLC 
reported no difference in 1-year survival between platinum-
doublets and nonplatinum regimens with third-generation 
agents, leaving space for further development of platinum-
free strategies in the first-line setting.32
Gemcitabine in elderly patients
Given the toxicity generally associated with conventional 
chemotherapy and the modest survival advantage obtained 
with cytotoxic agents, the role of systemic treatments for 
elderly patients has been under debate for years. A review of 
2531 patients treated by SWOG investigators for advanced 
NSCLC between 1974 and 1988 showed that age over 
70 years represents an independent predictor of improved 
survival.33 In addition, another retrospective study performed 
to assess the tolerance of chemotherapy in elderly patients 
enrolled in phase II trials showed no difference in outcome 
between younger and older subjects with a cut-off of 
65 years.34 The ELVIS trial, a randomized phase III study 
of vinorelbine vs best supportive care, provided the first 
compelling evidence that elderly patients can derive a sub-
stantial benefit from chemotherapy.35 The results from this 
study encouraged the investigation of other third-generation 
cytotoxic agents in this setting. Gemcitabine single agent 
has been tested in multiple phase II trials with response 
rates up to 38% and median survival up to 9 months in 
Table 2 Phase iii trials comparing new generation nonplatinum-based 
with platinum-based regimens
Trial Regimens N RR 
(%)
OS 
(months)
pa
Gridelli23 GC 250 30 8.9 NS
vC
Gv 251 25 7.5
Laack24 GvC 144 28.3b 7.6 NS
Gv 143 13.0 8.4
Kubota25 PCb 197 37b 14.1 NS
Gv → D 196 25 13.6
Georgoulias26 vC 192 39 9.7 NS
GD 197 30 9.0
Pujol28 vC 156 36 9.6 NS
GD 155 31 11.1
Kosmidis29 PCb 252 28 10.4 NS
GP 257 35 9.8
Kosmidis30 GCb 227 27 10.5 NS
GP 225 31 10.0
Smit31 PC 159 32 8.1 NSc
GC 160 37 8.9
GP 161 28 6.7  
arelated to overall survival. bsignificantly higher. cPC versus each other regimen.
Abbreviations: C, cisplatin; Cb, carboplatin; D, docetaxel; G, gemcitabine; P, paclitaxel; 
V, vinorelbine; RR, response rate; OS, overall survival; NS, not significant.OncoTargets and Therapy 2009:2 213
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patients over 70 years of age.36–38 To optimize the activity 
of single-agent schedules, gemcitabine has been combined 
with different partners, including vinorelbine and taxanes. 
Investigators from the Southern Italy Cooperative Oncology 
Group conducted a phase III study to assess whether the 
addition of gemcitabine to vinorelbine could lead to improved 
outcome over vinorelbine alone in patients with advanced 
NSCLC  70 years of age.39 An interim analysis led to an 
early termination of the study due to the clear advantage 
favoring the combination arm in terms of reduced risk of 
death (HR 0.48, P  0.01). However, the poor outcome for 
patients in the single agent arm was not comparable with 
historical controls, thus precluding any firm conclusion. 
Moreover, in the larger MILES trial of GV vs gemcitabine 
vs vinorelbine the combination arm was not associated with 
improved outcome but rather with increased toxicity discour-
aging the introduction of this regimen in clinical practice.40
The association of gemcitabine and taxanes has been 
extensively studied in phase II trials with response rates 
averaging approximately 30%.41–44 A pooled analysis of 
six clinical trials conducted by the Hellenic Oncology 
Research Group showed comparable efficacy and toxicity of 
GD combinations between younger (70 years) and older 
(70 years) patients.45 However, a recently published phase 
III trial of GD vs docetaxel alone in elderly patients and 
subjects with poor performance status showed no survival 
improvement for the combination arm, suggesting that single 
agent chemotherapy should remain the standard of care for 
these groups of patients.46
In the attempt to shed some light on gemcitabine-based 
doublets vs single-agent therapy for elderly patients with 
advanced NSCLC, Italian investigators have recently 
published a literature-based metanalysis pooling data from 
four phase III trials.47 The authors observed a significant 
difference in terms of response rate favoring gemcitabine-
based doublets with a trend toward improved 1-year 
survival. Toxicities were comparable, except for increased 
grade 3 and 4 thrombocytopenia for patients treated with 
doublets. Overall, these findings address the need for 
further prospective studies to identify the optimal role for 
nonplatinum-based treatments in this setting.
Gemcitabine in association  
with targeted agents
Recent advances in the molecular knowledge of cancer led 
to the development of targeted agents aimed at disrupting 
pathways that are essential for the survival and progression 
of human malignancies. In the last few years a multitude of 
new compounds has been tested either alone or in association 
with conventional chemotherapy with the ultimate goal of 
improving the outcome of patients with advanced NSCLC. 
The Epidermal Growth Factor Receptor (EGFR) has been 
one of the most attractive and investigated targets, because 
of its common overexpression in NSCLC. Erlotinib and gefi-
tinib, two orally available EGFR tyrosine kinase inhibitors, 
showed encouraging activity as single agents in unselected 
patients with advanced NSCLC treated in the context of 
phase II studies.48–51 Nevertheless, only erlotinib was able to 
offer a significant survival advantage over best supportive 
care in pretreated unselected patients,52 with subsequent 
approval by regulatory agencies in several countries. Four 
large phase III randomized trials were performed to ascer-
tain whether the addition of either erlotinib or gefitinib to 
standard first line chemotherapy, including gemcitabine and 
cisplatin, could improve survival in untreated NSCLC.53–56 
Disappointingly, all these studies failed to meet their primary 
endpoint, possibly due to the lack of patient selection. In fact, 
it is currently known that EGFR tyrosine kinase inhibitors 
are particularly active in patients harboring EGFR tyrosine 
kinase domain mutations and/or EGFR gene gain.57–59 
Whether the addition of chemotherapy to EGFR tyrosine 
kinase inhibitors in biologically selected patients might 
provide any further benefit is as yet unknown and prospective 
trials addressing this issue are warranted.
Other anti-EGFR strategies include the use of monoclonal 
antibodies directed against the extracellular domain of the 
protein, such as cetuximab. In a phase III trial of VC with or 
without cetuximab in EGFR overexpressing NSCLC, patients 
allocated in the experimental arm experienced significantly 
longer survival, a finding that might substantially impact 
on the treatment strategies for chemonaive patients.60 The 
drug has been also studied in association with gemcitabine/
platinum-based doublets in a randomized phase II trial.61 
Interestingly, EGFR overexpression at immunohistochem-
istry was not an inclusion criterion. The noncomparative 
nature of the trial precludes any firm conclusion, but it 
should be noted that patients who received cetuximab had 
better response rate, progression-free survival and overall 
survival, suggesting that cetuximab might synergize with 
gemcitabine/platinum doublets and be responsible for the 
observed improved outcome.
More recently, inhibition of angiogenesis has emerged as 
a potentially effective strategy in controlling tumor growth.62 
Bevacizumab, an anti-VEGF monoclonal antibody, has been 
shown to increase survival when added to a standard PCb 
regimen in patients with advanced nonsquamous NSCLC and OncoTargets and Therapy 2009:2 214
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no brain metastases in a large phase III trial.63 Nevertheless, 
the addition of bevacizumab has been significantly associated 
with greater grade 3 and 4 toxicity and with more treatment-
related deaths, possibly because of the dose used (15 mg/kg 
on day 1 every 3 weeks). The agent has been also tested 
in combination with GC in a recently published phase III 
study.64 In the AVAil trial 1043 patients with nonsquamous 
NSCLC and lack of brain metastases were randomly assigned 
to GC alone vs GC plus low-dose bevacizumab (7.5 mg/kg) 
or GC plus high-dose bevacizumab (15 mg/kg). The primary 
endpoint has been amended from overall survival to pro-
gression-free survival. The trial confirmed the activity of 
bevacizumab in this group of patients, with significantly 
prolonged progression-free survival in both the experimen-
tal arms (HR 0.75, P = 0.003 and HR 0.82, P = 0.03 for 
low- and high-dose vs placebo, respectively). Importantly, 
the addition of bevacizumab was not associated with a 
greater incidence of grade 3 or 4 adverse events, suggesting 
that gemcitabine and cisplatin represent effective and safe 
partners for this agent.
Pharmacogenomic approaches  
to gemcitabine-based chemotherapy
The improvement of molecular biology techniques has helped 
to better elucidate the mechanism of action of cytotoxic 
agents and has led to the identification of markers related to 
sensitivity or resistance to specific compounds, ultimately 
contributing to the concept of customized chemotherapy. In 
fact, it has been hypothesized that the evaluation of multiple 
biomarkers on tumor tissue might help to select the optimal 
cytotoxic treatment for each patient.
A number of molecular predictors of gemcitabine activity 
have been characterized. In vitro data showed that basal levels 
of the major gemcitabine transporter – hENT1 – are directly 
correlated with the IC50 of the drug in a panel of 22 NSCLC 
cell lines,65 although no clinical data to corroborate this 
finding have been reported. Growing interest has been 
generated by dCK, the rate-limiting enzyme in the biotrans-
formation of gemcitabine. While pretreatment levels of dCK 
have not been associated with drug sensitivity, decreased 
dCK expression has been observed in a model of acquired 
resistance to gemcitabine, suggesting that dCK reinduction 
might restore sensitivity.65 Interestingly, although no dCK-
inactivating mutations have been described so far, recent 
findings suggest that dCK polymorphisms might influence 
dCK expression and, ultimately, gemcitabine activity in 
pancreatic cancer.66,67 This observation, which should be 
extended to NSCLC patients, suggests dCK genotyping 
might help to identify sensitive/resistant subjects, although 
more robust data need to be produced.
Other biomarkers that have been studied include 
enzymes that might lead to early gemcitabine inactivation, 
like 5´-nucleotidase (5´NT), and CDA. While low levels 
of 5´NT have been observed in tumor cell lines resistant 
to gemcitabine,68 a recent immunohistochemical study in 
43 NSCLC patients with advanced disease indicated that low 
5´NT expression is an independent predictor for increased 
survival for subjects exposed to the drug.69 The limited 
sample size of the study precludes any firm conclusion and 
certainly deserves further investigation in larger cohorts of 
patients. Studies aimed at correlating CDA mRNA expres-
sion with outcome in gemcitabine-treated patients, particu-
larly with pancreatic cancer, produced conflicting results.70,71 
Similarly, most of the reports that have investigated the role 
of CDA polymorphisms in predicting gemcitabine activity 
failed to show any association with drug activity,72,73 although 
multiple findings seem to indicate that different CDA genetic 
variants might influence gemcitabine pharmacokinetics, with 
an ultimate impact on the toxicity of the compound.74,75
Being a major target of gemcitabine, RR has been widely 
investigated in cohorts of NSCLC patients treated with the 
drug, with specific attention for the RRM1 subunit.76–79 
Most of the studies showed that RRM1 mRNA expression 
was associated with significantly longer overall survival 
in patients who received a gemcitabine-based doublet 
both in the neoadjuvant and palliative setting,76–79 while it 
represented a prognostic factor for decreased survival for 
patients who underwent surgery alone.80 In addition, also 
RRM1 polymorphisms have been correlated with outcome 
in NSCLC patients treated with gemcitabine,81 despite the 
lack of a clear association between different haplotypes and 
RRM1 expression.81,82 These findings led investigators to 
perform a randomized phase II trial aimed at customizing 
treatment based on ERCC1 – a predictor for platinum com-
pounds activity83 – and RRM1 expression in 85 chemonaive 
NSCLC patients with advanced disease84 Based on tumor 
expression of these two biomarkers, doublets including 
carboplatin, gemcitabine, vinorelbine and docetaxel were 
selected. This customized approach led to a response rate 
of 44% and to a disease-free and overall survival of 6.6 and 
13.6 months, respectively, encouraging further evaluation of 
genomic-driven strategies in phase III trials.
Conclusions
Gemcitabine in association with cisplatin represents an 
active combination against NSCLC, and has been selected OncoTargets and Therapy 2009:2 215
Gemcitabine in advanced NSCLC Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
as the reference regimen for the first-line setting in several 
European countries. The pivotal role of this doublet has been 
corroborated by robust pharmacoeconomic data addressing 
the cost-effectiveness of the GC regimen compared with other 
new generation platinum-based combinations. Advances in 
the molecular knowledge of cancer and the development of 
sophisticated biological assays have enabled the safe and 
effective combination of gemcitabine with different new targeted 
agents and the identification of biomarkers that might be poten-
tially used for prospective patient selection. In fact, customized 
treatments represent the next big step that medical oncologists 
are trying to pursue, with the ultimate goal of offering cancer 
patients active and safe options in their battle against cancer.
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